Biosearch Technologies Awarded Second Phase II Army SBIR Grant
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Biosearch Technologies, Inc. (Biosearch), has announced that the company has been awarded another Phase II Small Business Innovative Research (SBIR) grant from the Department of Defense (DoD). The purpose of the $750,000+ Phase II grant is to continue the design and development of accurate assays for pathogens of military importance.
The assays will be based on quantitative Polymerase Chain Reaction (qPCR) modified for field deployment in overseas military operations. The grant includes assays for six rickettsial pathogens, four of which are listed in the top 25 of the Global Risk-Severity Index (GRSI) compiled by the Armed Forces Medical Intelligence Center (AFMIC). In addition, several of these agents are listed as Category A or B Priority Pathogens by the National Institute of Allergy and Infectious Diseases (NIAID). The grant also covers development of Analyte Specific Reagents (ASRs).
Jerry Ruth, PhD, Director of Research and Development at Biosearch Technologies, is the Principal Investigator of the award. Dr Ruth comments, “Stable field-deployable reagents for the rapid detection of highly infectious and often lethal pathogens in the field of military operations are of high importance. Such reagents will also be useful in determining the environmental source of each pathogen.” Last month, Biosearch was awarded an $800,000+ Phase II grant from DoD for the design and development of assays for six arbovirus pathogens.
The assays will be based on quantitative Polymerase Chain Reaction (qPCR) modified for field deployment in overseas military operations. The grant includes assays for six rickettsial pathogens, four of which are listed in the top 25 of the Global Risk-Severity Index (GRSI) compiled by the Armed Forces Medical Intelligence Center (AFMIC). In addition, several of these agents are listed as Category A or B Priority Pathogens by the National Institute of Allergy and Infectious Diseases (NIAID). The grant also covers development of Analyte Specific Reagents (ASRs).
Jerry Ruth, PhD, Director of Research and Development at Biosearch Technologies, is the Principal Investigator of the award. Dr Ruth comments, “Stable field-deployable reagents for the rapid detection of highly infectious and often lethal pathogens in the field of military operations are of high importance. Such reagents will also be useful in determining the environmental source of each pathogen.” Last month, Biosearch was awarded an $800,000+ Phase II grant from DoD for the design and development of assays for six arbovirus pathogens.